Latest News for: familial hypercholesterolemia
Edit
Homozygous Familial Hypercholesterolemia Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | ...
GetNews 12 Jun 2025
Edit
YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)
PR Newswire 06 Jun 2025
Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for YOLT-101, an in vivo base editing therapy targeting PCSK9 for the treatment of heterozygous familial hypercholesterolemia (HeFH).
Edit
Repair Biotechnologies Receives Orphan Drug Designation From the FDA for the Treatment of Homozygous Familial Hypercholesterolemia
Pharmiweb 19 May 2025
Food and Drug Administration (FDA) has granted Orphan Drug Designation to its drug REP-0003 for the treatment of patients with homozygous familial hypercholesterolemia (HoFH), a rare condition of accelerated atherosclerosis ... Contact Information ... .
- 1